The next big AI market may be hiding between the doctor and the pharmacy A doctor writes a prescription. That should be the easy part. Instead, patients can get stuck between insurers, pharmacies, financial-assistance programs and layers of paperwork before
Biotech is one of the few areas of the stock market where a company can look completely different by the end of a single trading day. A positive clinical trial can suddenly turn an overlooked drug into a serious commercial
Lilly is making a larger bet on depression treatment Eli Lilly is moving deeper into neuroscience with a deal to acquire AtaiBeckley, a clinical-stage biopharmaceutical company developing experimental therapies for treatment-resistant depression. AtaiBeckley stock jumped 30% in pre-market trading Thursday
Nvidia is turning general AI agents into specialized research assistants Nvidia is expanding its healthcare and life-sciences business with a new software platform designed to help AI agents perform complex scientific work. The BioNeMo Agent Toolkit connects general-purpose AI systems
A major funding round just validated one of biotech’s most-watched AI platforms Isomorphic Labs said it raised $2.1 billion in a new financing round, with Thrive Capital returning as lead investor and existing backers Alphabet and GV also participating, alongside
A stronger debut just added to biotech’s improving IPO tone Odyssey Therapeutics opened at $20, above its $18 IPO price, in a debut that gave the Boston-based biotech an initial public valuation just under $900 million. That followed an upsized
What Happened Eli Lilly said it will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, giving the drugmaker a bigger foothold in next-generation cell therapy and cancer treatment. Lilly said it will pay $3.25 billion
What Happened UnitedHealth Group (UNH) and other major health insurers rallied on Tuesday after the Centers for Medicare & Medicaid Services, or CMS, said it would increase payments for Medicare Advantage plans next year. The agency said payments to insurers
From Europe’s Most Valuable Company to Market Reality Novo Nordisk’s meteoric rise during the Wegovy era has officially come full circle. Shares of the Danish drugmaker plunged more than 16%, wiping out the remaining gains tied to the explosive growth
Novo Nordisk Pushes Back on $49 Wegovy Alternative Novo Nordisk said Thursday it will pursue legal and regulatory action against Hims & Hers after the telehealth firm announced plans to sell a low-cost copy of Novo’s blockbuster Wegovy weight loss
The next big AI market may be hiding between the doctor and the pharmacy A
Biotech is one of the few areas of the stock market where a company can
Lilly is making a larger bet on depression treatment Eli Lilly is moving deeper into
Nvidia is turning general AI agents into specialized research assistants Nvidia is expanding its healthcare
A major funding round just validated one of biotech’s most-watched AI platforms Isomorphic Labs said
A stronger debut just added to biotech’s improving IPO tone Odyssey Therapeutics opened at $20,
What Happened Eli Lilly said it will acquire biotech company Kelonia Therapeutics in a deal
What Happened UnitedHealth Group (UNH) and other major health insurers rallied on Tuesday after the
From Europe’s Most Valuable Company to Market Reality Novo Nordisk’s meteoric rise during the Wegovy
Novo Nordisk Pushes Back on $49 Wegovy Alternative Novo Nordisk said Thursday it will pursue
